

To: Ann Marie Gordon or Linda
Washington State Toxicology Lab

Fax: 207-871-5751

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCT, Grey Top, 16x100, 10ml	375174/127807/212210

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

THE KENDALL COMPANY LP

COUNTY OF BRISTOL
COMMONWEALTH OF MASSACHUSETTS



David A. Olson
Vice President Regulatory Affairs

Subscribed and sworn to before me
on this 7th day of October, 2002.



Karen A. Tabaczynski, Notary Public
My commission expires 8/15/2008

Date: October 7, 2002

RECEIVED

OCT 15 2002

WSP TOX LAB

To: Ann Marie Gordon or Linda
Washington State Toxicology Lab

Fax: 207-871-5751

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCT, Grey Top, 16x100, 10ml	221211

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

THE KENDALL COMPANY LP



David A. Olson
Vice President Regulatory Affairs

Subscribed and sworn to before me
on this 17th day of
October 2003.

Notary 
My commission expires on 11/28/2008

Date: October 17, 2003

To: Ann Marie Gordon or Linda
Washington State Toxicology Lab

Fax: 207-871-5751

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

<u>Product Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCT, Grey Top, 16x100, 10ml	224631

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	<u>Range</u>	<u>Nominal</u>
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

THE KENDALL COMPANY LP


David A. Olson
Vice President Regulatory Affairs

Subscribed and sworn to before me
on this 17th day of
October 2003.

Notary 
My commission expires on 11/28/2008

Date: October 17, 2003

Date: November 21, 2002

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way South
Suite 360
Seattle, Washington 98134RECEIVED
NOV 27 2002
WSP TOX LAB**CERTIFICATE OF COMPLIANCE**

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.


Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCT, Grey Top, 16x100, 10ml	226210

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

THE KENDALL COMPANY LP

David A. Olson
Vice President Regulatory AffairsSubscribed and sworn to before me
on this 21st day of
November 2002.Notary 
My commission expires on 11/28/2008

To: Ann Marie Gordon or Linda
Washington State Toxicology Lab

Fax: 207-871-5751

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCT, Grey Top, 16x100, 10ml	230114

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	<u>Range</u>	<u>Nominal</u>
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

THE KENDALL COMPANY LP



David A. Olson
Vice President Regulatory Affairs

Subscribed and sworn to before me
on this 17th day of
October 2003.

Notary 
My commission expires on 11/28/2008

Date: October 17, 2003

To: Ann Marie Gordon or Linda
Washington State Toxicology Lab

Fax: 207-871-5751

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCT, Grey Top, 16x100, 10ml	316842

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

THE KENDALL COMPANY LP



David A. Olson
Vice President Regulatory Affairs

Subscribed and sworn to before me
on this 17th day of
October 2003.

Notary 
My commission expires on 11/28/2008


Date: October 17, 2003



Healthcare

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000
Fax: 508-261-8145
www.tycohealthcare.com



To: Ann Marie Gordon
Washington State Toxicology Lab

Fax: 207-871-5751

CERTIFICATE OF COMPLIANCE


This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCT, Grey Top, 16x100, 10ml	328710


This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	<u>Range</u>	<u>Nominal</u>
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml




David A. Olson 2/24/04
Vice President Regulatory Affairs

On this 24th day of February, 2004, before me, the undersigned notary public, personally appeared DAVID OLSON, proved to me through satisfactory evidence of identification, which were personally known to be the person whose name is signed on the preceding or attached document in my presence.



Notary Public
My commission expires: 3-22-2007

Date: February 24, 2004



tyco

Healthcare

RECEIVED
SEP 23 2004
WSP TOX LAB

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000
Fax: 508-261-8145
www.tycohealthcare.com

To: Ann Marie Gordon
Washington State Toxicology Lab

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCS GRA 16X100 10ML P.O+F	334817

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	<u>Range</u>	<u>Nominal</u>
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

David A. Olson

David A. Olson
Vice President Regulatory Affairs

On this 28th day of April, 2004, before me, the undersigned notary public, personally appeared DAVID A. OLSON, proved to me through satisfactory evidence of identification, which were personally known to be the person whose name is signed on the preceding or attached document in my presence.

Suzanne E. Gaddy
Notary Public

My commission expires: 3-22-2007

Date: April 27, 2004

SUZANNE E. GADDY
NOTARY PUBLIC
COMMONWEALTH OF MASSACHUSETTS
MY COMMISSION EXPIRES MARCH 22, 2007

tyco

Healthcare

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000

Fax: 508-261-8145

www.kendallhq.com

Kendall

RECEIVED

AUG 13 2002

WSP TOX LAB


CERTIFICATE OF COMPLIANCE

To: Manny Garcia
Scientific Supply & Equipment
Fax: 206-389-2738

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Requirements and Kendall specifications, and that the subject product(s) comply with all requirements.

<u>Product Code</u>	<u>Lot Number</u>	<u>Description</u>
8881352788	374905	BCS GRA 16x100 10mL P.O+F


David Olson
Vice President Regulatory Affairs


Jonetha Owens
Notary
My commission Expires 11/28/2008

Date: November 21, 2002

RECEIVED
NOV 27 2002
WSP TOX LAB

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way South
Suite 360
Seattle, Washington 98134

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.


Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCT, Grey Top, 16x100, 10ml	376710

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	<u>Range</u>	<u>Nominal</u>
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

THE KENDALL COMPANY LP



David A. Olson
Vice President Regulatory Affairs

Subscribed and sworn to before me
on this 21st day of
November 2002.

Notary 
My commission expires on 11/28/2008

RECEIVED
SEP 23 2004
WSP TOX LAB

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S. Ste 360

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCS GRA 16X100 10ML P.O+F	419815

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:


	<u>Range</u>	<u>Nominal</u>
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

David A. Olson
David A. Olson
Vice President Regulatory Affairs

On this 20th day of September, 2004, before me, the undersigned notary public, personally appeared D. DAVID A. OLSON, proved to me through satisfactory evidence of identification, which were personally known to be the person whose name is signed on the preceding or attached document in my presence.

Suzanne E. Gaddy
Notary Public
My commission expires: 3-22-2007

Date: September 17, 2004





To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S. Ste 360

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

Product

<u>Code</u>	<u>Description</u>	<u>Lot #</u>
8881-352788	BCS GRA 16X100 10ML P.O+F	423512

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml


David A. Olson

David A. Olson
Vice President Regulatory Affairs

On this 11th day of November, 2004, before me, the undersigned notary public, personally appeared DAVID A. OLSON, proved to me through satisfactory evidence of identification, which were personally known to be the person whose name is signed on the preceding or attached document in my presence.

Suzanne E. Gaddy
Notary Public
My commission expires: 3-22-2007

Date: November 11, 2004



tyco

Healthcare


15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000
www.kendallhq.com



To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S Suite 360

Via Fax: 206-262-6145



Certificate of Compliance

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot</u>
8881352788	BCS GRA 16X100 10ML P.O+F	431713

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0 -26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml

David Olson
Vice President Regulatory Affairs

On this 3rd day of March, 2005, before me, the undersigned notary public, personally appeared David Olson, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the preceding or attached document in my presence.

Notary Public
My Commission expires: Dawn M. Pawlitschek
NOTARY PUBLIC
My commission expires Apr. 17, 2009

March 3, 2005



Healthcare

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000
Fax: 508-261-8461

www.kendallhq.com

Kendall

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S Suite 360

Via Fax: 206-262-6145

Certificate of Compliance

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot</u>
8881352788	BCS GRA 16X100 10ML P.O+F	501308


This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	<u>Range</u>	<u>Nominal</u>
Potassium Oxalate	15.0 -26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml



David Olson
Vice President Regulatory Affairs

On this 20 day of June, 2005, before me, the undersigned notary public, personally appeared DAVID OLSON, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the preceding or attached document in my presence.




Notary Public
My Commission expires: Dawn M. Pawlitschek
NOTARY PUBLIC
My commission expires Apr. 17, 2009

June 20, 2005

Kendall

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S Suite 360
Seattle, WA 98134-2027

Via Fax: 206-262-6145



Certificate of Compliance

This is to certify that the product(s) listed below were manufactured and inspected in accordance with FDA Quality System Regulations, Kendall product specifications and NCCLS guidelines, and that the subject product(s) comply with all requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot</u>
8881352788	BCS GRA 16X100 10ML P.O+F	515729

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycolytic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0 -26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw Volume	9.0-11.0ml	10ml


David Olson
Vice President Regulatory Affairs

On this 6 day of July, 2005, before me, the undersigned notary public, personally appeared DAVID OLSON, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the preceding or attached document in my presence.


Notary Public
My Commission expires: Dawn M. Pawlitschek
NOTARY PUBLIC
My commission expires Apr. 17, 2009

July 5, 2005

Kendall

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

Fax: 206-389-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	521202

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml



David A. Olson
Vice President Regulatory Affairs

On this 16 day of November, 2005, before me the undersigned notary public, personally appeared DAVID A OLSON, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the proceeding or attached document in my presence.


Notary Public

My commission expires:

Dawn M. Pawlitschek
NOTARY PUBLIC
My commission expires Apr. 17, 2009

Date: November 16, 2005



Healthcare

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000

Fax: 508-261-8461

www.kendallhq.com

Kendall

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	521804

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:


	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml

David A. Olson
Vice President Regulatory Affairs

On this 23rd day of November 2005, before me the undersigned notary public, personally appeared DAVID OLSON, proved to me through satisfactory evidence of identification, which were personally known to be the person whose name is signed on the proceeding or attached document in my presence.

Notary Public
My commission expires: 3-22-2007

Date: November 22, 2005





Healthcare

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000
Fax: 508-261-8461

www.kendallhq.com

Kendall

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	525504

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:


	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml

David A. Olson
Vice President Regulatory Affairs

On this 23rd day of November, 2005, before me the undersigned notary public, personally appeared David Olson, proved to me through satisfactory evidence of identification, which were personally known to be the person whose name is signed on the proceeding or attached document in my presence.

Notary Public
My commission expires: 3-22-2007

Date: November 22, 2005





Healthcare

Kendall

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000
Fax: 508-261-8461

www.kendallhq.com

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	531612

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml



David A. Olson
Vice President Regulatory Affairs

On this 24 day of March, 2006, before me the undersigned notary public, personally appeared David Olson, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the proceeding or attached document in my presence.



Notary Public
My commission expires: Dawn M. Pawlitschek
NOTARY PUBLIC

My commission expires: Apr 17, 2009

Date: March 23, 2006



Healthcare

Kendall

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000
Fax: 508-261-8461

www.kendallhq.com

RECEIVED

APR 17 2006

WSP TOX LAB

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	602704

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	<u>Range</u>	<u>Nominal</u>
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml



David A. Olson
Vice President Regulatory Affairs

On this 7 day of April, 2006, before me the undersigned notary public, personally appeared David Olson, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the proceeding or attached document in my presence.



Notary Public
My commission expires: Dawn M. Pawlitschek
NOTARY PUBLIC
My commission expires Apr. 17, 2009

Date: April 6, 2006



Healthcare

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000

Fax: 508-261-8461

www.kendallhq.com

Kendall

To: Ms. Linda Collins
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	604104

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml

David A. Olson
Vice President Regulatory Affairs

On this 25 day of July, 2006, before me the undersigned notary public, personally appeared DAVID A. OLSON, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the proceeding or attached document in my presence.

Notary Public

My commission expires:

Dawn M. Pawlitschek
NOTARY PUBLIC
My commission expires Apr. 17, 2009

Date: July 14, 2006



Healthcare

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000

Kendall

www.tycohealthcare.com

To: Ms. Kim Miller
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.


<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	615514

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml


 David A. Olson
 Vice President Regulatory Affairs

On this 13 day of October 2006, before me the undersigned notary public, personally appeared DAVID OLSON, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the proceeding or attached document in my presence.


 Notary Public
 My commission expires: Dawn M. Pawlitschek
 NOTARY PUBLIC
 My commission expires Apr. 17, 2009

Date: October 12, 2006

tyco

Healthcare

15 Hampshire Street
Mansfield, MA 02048

Tel: 508-261-8000

Kendall

RECEIVED

www.tycohealthcare.com

To: Ms. Kim Miller
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

JAN 8 2007

WSP TOX LAB

Fax: 206-262-6145

CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	623312

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml

David A. Olson

David A. Olson
Vice President Regulatory Affairs

On this 4 day of JANUARY 2007, before me the undersigned notary public, personally appeared DAVID A. OLSON, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the proceeding or attached document in my presence.

Dawn M. Pawlitschek

Notary Public
My commission expires:

Dawn M. Pawlitschek
NOTARY PUBLIC
My commission expires Apr. 17, 2009

Date: January 2, 2007

Kendallwww.tycohealthcare.com**RECEIVED**

JAN 8 2007

WSP TOX LABTo: Ms. Kim Miller
Washington State Toxicology Lab
2203 Airport Way S. Ste 360
Seattle, WA 98134

Fax: 206-262-6145


CERTIFICATE OF COMPLIANCE

This is to certify that the products listed below are in compliance with the current FDA Quality System Requirements (QSR) as stipulated in 21 CFR Part 820. Representative product was inspected and tested in accordance with current Kendall specifications and quality requirements.

<u>Product #</u>	<u>Description</u>	<u>Lot #</u>
8881352788	BCS GRA 16X100 10ML P.O+F	629812

This tube was designed for laboratory procedures requiring plasma or whole blood and chemistry procedures where glycoltic inhibition of the specimen is required. The tube was manufactured to the following specifications:

	Range	Nominal
Potassium Oxalate	15.0-26.0mg	20mg
Sodium Fluoride	20.0-32.0mg	25mg
Draw volume	9.0-11.0ml	10ml


David A. Olson
Vice President Regulatory Affairs

On this 4 day of January 2007, before me the undersigned notary public, personally appeared DAVID A. OLSON, proved to me through satisfactory evidence of identification, which were personal knowledge to be the person whose name is signed on the proceeding or attached document in my presence.



Notary Public

My commission expires: Dawn M. Pawlitschek
NOTARY PUBLIC

My commission expires Apr. 17, 2009

Date: January 2, 2007